Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.

There are errors in the cytokine release syndrome (“CRS”) section of Table 2 on page 5417. In the “ELIANA” column, the median number of days to onset should read “3,” the range of days to onset should read “1-22,” the median number of days of duration should read “8,” and the range of days of duration should read “1-36.” In the “JULIET” column, the range of days to onset should read “1-51,” the median number of days of duration should read “7,” and the range of days of duration should read “2-30.”

In the “MRD⁻” row of the “Pivotal trial, % (95% CI)” column of Table 3 on page 5419, “100.0 (n = 64/64)” should read “98.5 (n = 64/65).”

The corrected Tables 2 and 3 are shown below. The errors have been corrected in the published article.